Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

32
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
32
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Prognosis biomarkers in MOGAD: What can we learn from observational studies?

Revue neurologique·2026
Same author

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Revue neurologique·2025
Same author

[Set your CLOCCS forward or get imMERSed!]

Journal francais d'ophtalmologie·2025
Same author

Teriflunomide, cognition and MRI: A longitudinal study.

Multiple sclerosis and related disorders·2024
Same author

Clinical applications of deep learning in neuroinflammatory diseases: A scoping review.

Revue neurologique·2024

Related Experiment Video

Updated: May 7, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

8.0K

[Natalizumab as induction therapy in multiple sclerosis].

A Corlobé1, M Charif1, A Mania2

  • 1Service de neurologie, CHU Gui-de Chauliac, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.

Revue Neurologique
|October 16, 2013
PubMed
Summary

Natalizumab effectively rendered three patients with aggressive relapsing-remitting multiple sclerosis (MS) disease-free after just one infusion. This suggests natalizumab could be a viable induction therapy for MS, especially in JC virus-negative individuals.

Keywords:
Induction therapyMultiple sclerosisNatalizumabSclérose en plaquesTraitement d’induction

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Related Experiment Videos

Last Updated: May 7, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

8.0K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Current first-line treatments for relapsing-remitting multiple sclerosis (MS), such as interferon-β and glatiramer acetate, offer limited efficacy and may not be suitable for all patients.
  • Induction therapy, utilizing potent early-stage treatments, aims to aggressively manage MS disease progression.
  • Natalizumab, a monoclonal antibody, is approved for MS treatment and effectively suppresses disease activity.

Observation:

  • Three patients with relapsing-remitting MS and high disease activity (indicated by multiple gadolinium-enhancing lesions) were treated with natalizumab.
  • Outcomes were assessed at 1 and 6 months post-initial natalizumab infusion.

Findings:

  • Following natalizumab treatment, all three patients exhibited no gadolinium-enhancing lesions or new T2 lesions on MRI scans.
  • Clinically, none of the patients experienced relapses during the 6-month observation period.
  • Patients achieved a 'disease activity free' status from the first natalizumab infusion.

Implications:

  • Natalizumab demonstrated dramatic efficacy as an induction therapy in these MS cases, rendering patients disease-free.
  • While not conventionally used as induction therapy due to potential toxicities of alternatives like mitoxantrone, natalizumab presents a promising option.
  • Natalizumab may serve as an effective alternative induction therapy for aggressive MS, particularly in JC virus-negative patients, warranting further investigation.